Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Jill Elizabeth Feldman"'
Autor:
Stephen Broderick, Megan E. Daly, Gaetano Rocco, Erin B. Kennedy, Mara B. Antonoff, Daniel H. Sterman, Shruti Jolly, Chad G. Rusthoven, Bryan J. Schneider, Bryan F. Meyers, Jill Elizabeth Feldman, Ben J. Slotman, Brendon M. Stiles
Publikováno v:
Journal of Clinical Oncology, 36(7), 710-719. American Society of Clinical Oncology
Schneider, B J, Daly, M E, Kennedy, E B, Antonoff, M B, Broderick, S, Feldman, J, Jolly, S, Meyers, B, Rocco, G, Rusthoven, C, Slotman, B J, Sterman, D H & Stiles, B M 2018, ' Stereotactic body radiotherapy for early-stage non-small-cell lung cancer: American society of clinical oncology endorsement of the American society for radiation oncology evidence-based guideline ', Journal of Clinical Oncology, vol. 36, no. 7, pp. 710-719 . https://doi.org/10.1200/JCO.2017.74.9671
Schneider, B J, Daly, M E, Kennedy, E B, Antonoff, M B, Broderick, S, Feldman, J, Jolly, S, Meyers, B, Rocco, G, Rusthoven, C, Slotman, B J, Sterman, D H & Stiles, B M 2018, ' Stereotactic body radiotherapy for early-stage non-small-cell lung cancer: American society of clinical oncology endorsement of the American society for radiation oncology evidence-based guideline ', Journal of Clinical Oncology, vol. 36, no. 7, pp. 710-719 . https://doi.org/10.1200/JCO.2017.74.9671
Purpose The American Society for Radiation Oncology (ASTRO) produced an evidence-based guideline on treatment with stereotactic body radiotherapy (SBRT) for patients with early-stage non–small-cell lung cancer. ASCO has a policy and set of procedur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bbbef83580c2d64781f63644afb003f
https://doi.org/10.1200/jco.2017.74.9671
https://doi.org/10.1200/jco.2017.74.9671
Autor:
Sanjib Basu, Michael J. Jelinek, Mary J. Fidler, Marta Batus, Nicole K. Yun, Lia Head, Philip Bonomi, Jill Elizabeth Feldman, Lauren Rynar
Publikováno v:
Journal of Clinical Oncology. 39:e24125-e24125
e24125 Background: Project PRIORITY, a collaborative research study between The EGFR Resisters and the LUNGevity Foundation, found that 29% of United States respondents had clinical depression. While tyrosine kinase inhibitors (TKI) prolong lives, th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7adde941f90153fca69a5655868f617c
https://doi.org/10.1200/jco.2021.39.15_suppl.e24125
https://doi.org/10.1200/jco.2021.39.15_suppl.e24125